表紙
市場調査レポート

抗がん剤・治療市場:データ・分析・予測

The Cancer Drugs & Treatments Market - Data, Analysis & Forecasts to 2023

発行 GMR Data Ltd 商品コード 301554
出版日 ページ情報 英文 243 Pages
即納可能
価格
本日の銀行送金レート: 1USD=106.02円で換算しております。
Back to Top
抗がん剤・治療市場:データ・分析・予測 The Cancer Drugs & Treatments Market - Data, Analysis & Forecasts to 2023
出版日: 2013年11月21日 ページ情報: 英文 243 Pages
概要

世界の癌治療薬・治療市場は2023年までに1,437億米ドルに達すると予測されています。抗がん治療市場はすでに774億米ドルの市場価値があり、新薬開発の最大分野・急成長分野のひとつであり続けると見られています。米国では2011年に3,220億米ドルの医療費が支出されましたが、2012年には市場の40.5%にあたる318億米ドルが、がん市場に支出されたと推計されています。

当レポートは、世界の抗がん剤・治療市場について調査し、今後5-10年間の予測を提供しており、がんの種類別による病因・症状・患者数、がん治療の種類、R&Dパイプライン・治療薬、主な課題、主要国の予測、抗がん剤トップ25それぞれの収益、および主要企業のプロファイルなどをまとめ、概略以下の構成でお届けいたします。

第1章 エグゼクティブサマリー

第2章 がんの種類;世界の人口に影響を及ぼす主要ながんの病因・症状・世界の患者数

  • 血液がんの種類・症状
  • 骨肉腫の種類・症状
  • 脳腫瘍の種類・症状
  • 消化管がんの種類・症状
  • 内分泌がんの種類・症状
  • 眼がんの種類・症状
  • 泌尿生殖器がんの種類・症状
  • 婦人科がんの種類・症状
  • 頭頸部がんの種類・症状
  • 呼吸器/肺がんの種類・症状
  • 皮膚がんの種類・症状
  • 世界のがん統計

第3章 がん;病因&影響 - がんに影響する要因、世界

  • 遺伝病
  • タバコ&喫煙
  • 運動・食習慣
  • ウィルス感染
  • 細菌感染
  • 年齢
  • 発がん性物質

第4章 がん治療の種類&副作用

  • 手術
  • 化学療法
  • 放射線療法
  • 標的療法
  • 免疫療法(生物学的療法)
  • ホルモン療法
  • 温熱療法
  • 幹細胞移植
  • その他の治療法

第5章 がん治療/治療薬市場の予測

  • 世界の標的療法市場
  • 世界の化学療法市場
  • 世界の免疫療法(生物学的療法)市場
  • 世界のホルモン療法市場

第6章 がんのR&Dパイプライン・治療薬

  • R&Dパイプライン

第7章 世界のがん治療薬市場における主な動向&課題

  • 主な動向
  • 主な課題

第8章 地域別の情勢:世界の主ながん治療薬市場

  • 米国
  • 英国
  • フランス
  • ドイツ
  • スペイン
  • イタリア
  • 日本
  • その他

第9章 がん市場における主要企業

第10章 専門家の見解

図表リスト

目次
Product Code: CAN1

GMR Data forecast that the global cancer drugs and treatments market will reach $143.7bn by 2023. GMR Data's latest report 'The Cancer Drugs & Treatments Market - Data, Analysis & Forecasts to 2023' explains just how this market will experience growth over the medium and long term. The report also highlights forecast for the next 5 and 10 years, so that you and your company can make specific long term plans. Don't let your competitors get the head-start on you, order this report today.

Have you seen the recent news on Cancer Drugs?

  • Merck's new cancer drug kept more than 4 of 5 melanoma patients alive for a year
  • Biopharma Alliances will be needed For Cancer Drugs in the cost conscious future - Forbes
  • EU approval for Bayer's prostate cancer drug
  • Sanofi ditches late-stage bone marrow cancer drug

The Anti-cancer treatment market is already worth $77.4bn (GMR Data) and continues to be one of the largest and fastest growing areas for new drug development - can you afford not to be involved? Should you and your company be capturing a greater market share?

Essential facts examined in this report

  • 1) Across 2013, 15 new molecular entities were approved by the FDA; out of which seven were for Oncology.
  • 2) Currently targeted therapies dominate the oncology pipeline, followed by chemotherapy.
  • 3) Immunotherapy drugs are gaining increasing amounts of attention due to fewer expected side effects.

Only by ordering this in-depth exclusive report will you have full access to the unique findings. This information is not available anywhere else. Find full details of these approved drugs alongside key cancer drugs in their testing phases in this new GMR Data report.

Discover exactly what the industry leaders are doing TODAY -

Within GMR Data's 'The Cancer Drugs & Treatments Market - Data, Analysis & Forecasts to 2023' we analyse the key cancer drugs and treatments in the market currently and how they will perform across the next decade.

Our study focuses on the individual revenues of the top 25 anti-cancer agents. With variable patents and the threat of generics, how will these key cancer drugs fare across the next decade? - ONLY THIS UNIQUE REPORT WILL TELL YOU

  • Rituxan
  • Herceptin
  • Avastin
  • Gleevec
  • Revlimid
  • Alimta
  • Velcade

PLUS - In-depth country analysis - Discover which countries and regions will drive the oncology drugs market to 2023?

The US spent $322bn on healthcare in 2011, GMR Data estimate that the US spent $31.8bn in the oncology market in 2012, capturing 40.5% of the market. 2nd to the US was Japan; spending $8.9bn in 2012, capturing 11.2%. The European mainstays of the pharmaceutical sector; the UK, Germany, France, Spain & Italy equated to 25% of the global oncology market in 2012.

But how will these country's markets develop? This report will tell you - TODAY

Exclusive Industry sourced information, not available anywhere else

As well as primary and secondary research sources, GMR Data have interviewed leading cancer specialists within big pharma, R&D, wholesalers, distributors, marketeers and key clinical organisations. From these interviews we have selected original, exclusive, transcribed interviews with leading specialists in their field - This information is not available anywhere else.

This GMR Data report is the single tool to equip you with the latest trends in all regional markets and why all stakeholders demand development of Cancer Drugs. This report will arm you with all you and your company require to develop, price, launch and market a cancer drug.

With over 240+ pages, and over 270+ charts, tables and graphs, this dedicated specialist report will ensure you remain equipped and fully informed, to succeed in this competitive market.

Table of Contents

Chapter 1 Executive Summary

  • 1.1 Cancer Drugs Market Review - How will the cancer drugs market grow to 2023? What is it worth today? Why?
  • 1.2 Chapter Breakdown
  • 1.3 Research and Analysis Methods - As well as the usual research tools; company fililngs, press releases, analyst knowledge, we also interviewed key decision makers / scientific researchers to gain an overall picture of the cancer drugs market.

Chapter 2 Types of Cancer; Causes, symptoms and global prevalance of the key cancers affecting the worlds population

  • 2.1 Blood Cancer Types and Symptoms
    • 2.1.2 Blood Cancer- Global Market
    • 2.1.3 Blood Cancer- Causes and Risk Factors
  • 2.2 Bone Cancer Types and Symptoms
    • 2.2.1 Bone Cancer- Global Market
    • 2.2.2 Bone Cancer Causes and Risk Factors
  • 2.3 Brain Cancer Types and Symptoms
    • 2.3.1 Brain Cancer Market- Global
    • 2.3.2 Brain Cancer- Causes and Risk Factors
  • 2.4 Breast Cancer Types and Symptoms
    • 2.4.1 Breast Cancer Market- Global
    • 2.4.2 Breast Cancer Causes and Risk factors
  • 2.5 Digestive/ Gastrointestinal Cancer Types and Symptoms
    • 2.5.1 Gastrointestinal Cancer Market- Global
    • 2.5.2 Gastrointestinal Cancer- Causes and Risk Factors
  • 2.6 Endocrine Cancers Types and Symptoms
    • 2.6.1 Endocrine Cancer Market- Global
    • 2.6.2 Endocrine Cancer- Causes and Risk Factors
  • 2.7 Eye Cancer Types and Symptoms
    • 2.7.1 Eye Cancer Market- Global
    • 2.7.2 Eye Cancer Causes and Risk Factors
  • 2.8 Genitourinary Cancers Types & Symptoms
    • 2.8.1 Genitourinary Cancer Market - Global
    • 2.8.2 Genitourinary Cancers - Causes and Risk Factors
  • 2.9 Gynaecologic Cancers Types & Symptoms
    • 2.9.1 Gynaecologic Cancer Market - Global
    • 2.9.2 Gynaecologic Cancers - Causes and Risk Factors
  • 2.10 Head & Neck Cancers Types & Symptoms
    • 2.10.1 Head and Neck Cancer Market - Global
    • 2.10.2 Head and Neck Cancer - Causes and Risk Factors
  • 2.11 Respiratory/Lung Cancers Types & Symptoms
    • 2.11.1 Respiratory Cancer Market - Global
    • 2.11.2 Respiratory Cancer - Causes and Risk Factors
  • 2.12 Skin Cancers Types & Symptoms
    • 2.12.1 Skin Cancer - Global Market
    • 2.12.2 Skin Cancer - Causes and Risk Factors
  • 2.13 Worldwide Cancer Facts and Statistics
    • 2.13.1 Cancer Incidence Facts & Statistics
    • 2.13.2 Cancer Mortality and Survival Facts & Statistics

Chapter 3 Cancer; Causes & Effects - Which factors effect the causes of cancers, globally.

  • 3.13 Genetic Causes
  • 3.14 Tobacco & Smoking
  • 3.15 Physical Activities and Eating Habits
  • 3.16 Viral Infections
  • 3.17 Bacterial Infections
  • 3.18 Age
  • 3.19 Carcinogens

Chapter 4 Cancer Treatment Types & Side Effects

  • 4.1 Surgery
    • 4.1.1 Potential Side effects of Surgery
  • 4.2 Chemotherapy - How will the mainstay of cancer treatment fair Vs. newer types of cancer treatment?
    • 4.2.1 Major Side effects of Chemotherapy
  • 4.3 Radiation Therapy
    • 4.3.1 Major Side effects of Radiation Therapy
  • 4.4 Targeted Therapy - Precision drugs; the future or too expensive for global use?
    • 4.4.1 Major Side effects of Targeted Therapy
  • 4.5 Immunotherapy (Biologic Therapy) - Great potential for some cancers, but lacking the wide range of other treatments?
    • 4.5.1 Major Side effects of Immunotherapy
  • 4.6 Hormonal Therapy
    • 4.6.1 Major Side effects of Hormone Therapy
  • 4.7 Hyperthermia
    • 4.7.1 Major Side effects of Hyperthermia
  • 4.8 Stem Cell Transplant
    • 4.8.1 Major Side effects of Stem Cell Transplant
  • 4.9 Other Therapies
    • 4.9.1 Photodynamic Therapy
    • 4.9.2 Side effects of Photodynamic Therapy
    • 4.9.3 Laser Treatment
    • 4.9.4 Side effects of Laser Treatment

Chapter 5 Cancer Therapies / Drugs Market Forecast

  • 5.1 Global Targeted Therapy Market - 2013 -2023
    • 5.1.1 Rituxan/MabThera by Roche - Rituxan faces the end of patent exclusivity in key areas across our forecast period; how greatly will this effect global revenue?
    • 5.1.2 Herceptin (Trastuzumab) by Roche - How will biosimilars affect Herceptin's bottom line in the near to mid future?
    • 5.1.3 Avastin (Bevacizumab) by Roche - What potential does Avastin have to enter the combination therapies market in the US/European markets?
    • 5.1.4 Gleevec (imatinib) by Novartis - Gleeva generated $4.7bn across 2012, how will this figure fair to 2023
    • 5.1.5 Velcade (Bortezomib) by Takeda (Millennium) and J&J - GMR Data forecast negative growth for Velcade to 2023, how & why?
    • 5.1.6 Tarceva (Erlotinib) by Roche - GMR Data forecast strong growth to 2018, which factors contribute to this forecast?
    • 5.1.7 Sutent (Sunitinib) by Pfizer - Sutent revenue increased by 4% between 2011 and 2012, find out why here.
    • 5.1.8 Sprycel (dasatinib) by Bristol Myers Squibb Sprycel's non-US sales revenue increased by 22% bewtween 2011 & 2012 ; find out which regions have driven this growth.
    • 5.1.9 Nexavar (Sorafenib) by Bayer and Onyx - How hard will the (expected) loss of patent exclusivity hit Nexavar's bottom line across our forecast period?
    • 5.1.10 Tasigna (Nilotinib) by Novartis - Tasigna is forecast to show strong growth throughout the forecast period - how & why?
    • 5.1.11 Afinitor / Votubia (Everolimus) by Novartis
    • 5.1.12 Xgeva (Denosumab) by Amgen
    • 5.1.13 Yervoy (ipilimumab) by Bristol-Myers Squibb
    • 5.1.14 Erbitux (cetuximab) by Bristol-Myers Squibb
  • 5.2 Global Chemotherapy Market - 2013 -2023
    • 5.2.1 Alimta (Pemetrexed) by Eli Lilly
    • 5.2.2 Xeloda (capecitabine) by Roche
    • 5.2.3 Eloxatin (oxaliplatin) by Sanofi-Aventis
    • 5.2.4 Temodar / Temodal (temozolomide) by Merck & Co.
    • 5.2.5 Vidaza (azacitidine) by Celgene
    • 5.2.6 Taxotere (docetaxel) by Sanofi-Aventis
    • 5.2.7 Treanda (bendamustine hydrochloride) by Teva Pharmaceuticals
  • 5.3 Global Immunotherapy (Biological therapy) Market - 2013 -2023
    • 5.3.1 Revlimid (lenalidomide) by Celgene
    • 5.3.2 Gardasil (Human Papillomavirus Quadrivalent) by Merck
    • 5.3.3 Zometa (zoledronate) by Novartis
  • 5.4 Global Hormone Therapy Market - 2013 -2023
    • 5.4.1 Faslodex (Fulvestrant) Injection by AstraZeneca
    • 5.4.2 Zoladex (Goserelin acetate implant) by AstraZeneca
    • 5.4.3 Arimidex (anastrozole) by AstraZeneca
    • 5.4.4 Casodex (bicalutamide) by AstraZeneca
    • 5.4.5 Sandostatin (octreotide acetate) by Novartis

Chapter 6 Cancer R&D Pipeline and Drugs

  • 6.1 R&D Pipeline
    • 6.1.1 Oncology Drugs; Recent Approvals
    • 6.1.2 Late Stage Cancer Drugs
    • 6.1.3 Key Experimental Cancer Drugs Pipeline
    • 6.1.4 Oncology Drug Pipeline - Cancer Drugs Failures

Chapter 7 Major Trends & Challenges in the Global Cancer Drugs Market

  • 7.1 Major Trends
    • 7.1.1 Personalised Medication
    • 7.1.2 Increasing Cancer Threat In Low & Middle Income Countries
    • 7.1.3 Antibody Drug Conjugates (ADC)
    • 7.1.4 Combination Therapy
    • 7.1.5 Key Collaborations and Alliances
    • 7.1.6 New Drug Development
    • 7.1.7 Immunotherapy - to be the next Industry Driver
  • 7.2 Major Challenges
    • 7.2.1 Expensive Treatment
    • 7.2.2 Biosimilars Competition
    • 7.2.3 Generic Competition
    • 7.2.4 Severe Side Effects of Cancer Care Treatment
    • 7.2.5 Regulatory Hurdles in Cancer Drug Approvals

Chapter 8 Regional Landscape - The Key Global Cancer Drug Markets

  • 8.1. The US Oncology Market to 2023
  • 8.2. The UK Oncology Market to 2023
  • 8.3. France Oncology Market to 2023
  • 8.4 The German Oncology Market to 2023
  • 8.5 The Spanish Oncology Market to 2023
  • 8.6 The Italian Oncology Market to 2023
  • 8.7 The Japanese Oncology Market to 2023
  • 8.8 The Rest of the World Oncology Market to 2023

Chapter 9 Major Players in the Oncology Market

  • 9.1 Amgen
  • 9.2 Ariad Pharmaceutical
  • 9.3 ASTELLAS PHARMA
  • 9.4 AstraZeneca
  • 9.5 Bayer healthcare pharmaceuticals
  • 9.6 Boehringer Ingelheim
  • 9.7 Bristol-Myers Squibb
  • 9.8 Celgene
  • 9.9 Eisai Co., Ltd.
  • 9.10 Eli Lilly & Co
  • 9.11 ImClone Systems Inc. (a subsidiary of Eli Lilly & Co)
  • 9.12 Exelixis
  • 9.13 GlaxoSmithKline
  • 9.14 Merck & Co
  • 9.15 Millennium Pharmaceuticals (Subsidiary of Takeda Oncology Company)
  • 9.16 Novartis Pharmaceuticals
  • 9.17 Onyx Pharmaceuticals
  • 9.18 Pfizer Inc.
  • 9.19 Roche
  • 9.20 Sanofi
  • 9.21 Teva Pharmaceuticals Industries

Chapter 10 Expert Opinion

  • 10.1 Dr John Marshall, Clinical Director of Oncology, Georgetown University Hospital
  • 10.2 Dr Anderson Ryan, Senior Group Leader at Gray Institute of Radiation, Oncology and Biology, at the University of Oxford
  • 10.3 Dr Ben Anderson, Professor of Surgery at the University of Washington & Chair of the Breast Health Global Initiative

List of Tables

  • Table 2.1.1.1 Major Drugs in Blood Cancer Market
  • Table 2.1.2.1 Major Bone Cancer Drugs in the Market
  • Table 2.1.3.1 Major Brain Cancer Drugs in Market
  • Table 2.1.4a Breast Cancer Incidences in US & UK
  • Table 2.1.4b Major Breast Cancer Drugs in Market
  • Table 2.1.5 Major Gastrointestinal Cancer Drugs in Market
  • Table 2.1.6 Major Endocrine Cancer Drugs in Market
  • Table 2.1.7 Major Eye Cancer drugs In the Market
  • Table 2.1.8 Major Genitourinary Cancers Cancer drugs In the Market
  • Table 2.1.9 Major Gynaecologic Cancer drugs In the Market
  • Table 2.1.10a Head & Neck Incidences in Asian Region - 2008
  • Table 2.1.10b Major Head and Neck Cancer Drugs in the Market
  • Table 2.1.11 Major Respiratory Cancer Drugs in the Market
  • Table 2.1.12 Major Skin Cancer Drugs in the Market
  • Table 4.1 Type of Cancer Surgeries
  • Table 4.3 Type of Radiation Therapy
  • Table 4.5 Types of Immunotherapy
  • Table 4.6 Types of Hormone Therapy
  • Table 4.7 Type or Ways of Hyperthermia Treatment
  • Table 4.8 Type of Stem Cell Transplant
  • Table 4.9.2 Type of Laser Treatments
  • Table 5.1.a: Global Targeted Therapy Market for Cancer Treatment: 2008-2012
  • Table 5.1.b: Global Targeted Therapy Market for Cancer Treatment: 2013-2023
  • Table 5.1.1.a: 2011 - 2012 Rituxan Sales Geographic Breakdown ($ bn)
  • Table 5.1.1.b: Rituxan Oncology Sales: 2008-2012
  • Table 5.1.1.c: Rituxan Sales & Forecast: 2013-2023
  • Table 5.1.2.a: Herceptin Sales: 2008-2012
  • Table 5.1.2.b: 2011 - 2012 Herceptin Sales Geographic Breakdown ($ bn)
  • Table 5.1.2.c: Herceptin Sales & Forecast: 2013-2023
  • Table 5.1.3.a: Avastin Sales: 2008-2012
  • Table 5.1.3.b: 2011 - 2012 Avastin Sales Geographic Breakdown ($ bn)
  • Table 5.1.3.c: Avastin Sales & Forecast: 2013-2023
  • Table 5.1.4.a: Gleevec Sales: 2008-2012
  • Table 5.1.4.b: 2011 - 2012 Gleevec Sales Geographic Breakdown ($ bn)
  • Table 5.1.4.c: Gleevec Sales & Forecast: 2013-2023
  • Table 5.1.5.a: Velcade Sales: 2008-2012
  • Table 5.1.5.b: 2011 - 2012 Velcade Sales Geographic Breakdown ($ bn)
  • Table 5.1.5.c: Velcade Sales & Forecast: 2013-2023
  • Table 5.1.6.a: Tarceva Sales: 2008-2012
  • Table 5.1.6.b: 2011 - 2012 Tarceva Sales Geographic Breakdown ($/m)
  • Table 5.1.6.c: Tarceva Sales & Forecast: 2013-2023
  • Table 5.1.7.a: Sutent Sales: 2008-2012
  • Table 5.1.7.b: Sutent Sales & Forecast: 2013-2023
  • Table 5.1.8.a: Sprycel Sales: 2008-2012
  • Table 5.1.8.b: 2011 - 2012 Sprycel Sales Geographic Breakdown ($ m)
  • Table 5.1.8.c: Sprycel Sales & Forecast: 2013-2023
  • Table 5.1.9.a: Nexavar Sales: 2008-2012 ($/bn)
  • Table 5.1.9.b: Nexavar Sales & Forecast: 2013-2023
  • Table 5.1.10.a: Tasigna Sales: 2008-2012
  • Table 5.1.10.b: 2011 - 2012 Tasigna Sales Geographic Breakdown ($ m)
  • Table 5.1.10.c: Tasigna Sales & Forecast: 2013-2023
  • Table 5.1.11.a: Afinitor Sales: 2008-2012
  • Table 5.1.11.b: 2011 - 2012 Afinitor Sales Geographic Breakdown ($ m)
  • Table 5.1.11.c: Afinitor Sales & Forecast: 2013-2023
  • Table 5.1.12.a: Xgeva Sales: 2008-2012
  • Table 5.1.12.b: 2011 - 2012 Xgeva Sales Geographic Breakdown ($ m)
  • Table 5.1.12.c: Xgeva Sales & Forecast: 2013-2023
  • Table 5.1.13.a: Yervoy Sales: 2011-2012
  • Table 5.1.13.b: 2011 - 2012 Yervoy Sales Geographic Breakdown ($ m)
  • Table 5.1.13.c: Yervoy Sales & Forecast: 2013-2023
  • Table 5.1.14.a: Erbitux Sales BMS: 2008-2012
  • Table 5.1.14.b: Erbitux Sales Merck KGaA: 2008-2012
  • Table 5.1.14.c: Erbitux Sales & Forecast: 2013-2023
  • Table 5.2.a: Global Chemotherapy Market for Cancer Treatment: 2008-2012
  • Table 5.2.b Market Size & Forecast - Chemotherapy Market 2013-2023
  • Table 5.2.1.a: Alimta Sales: 2008-2012
  • Table 5.2.1.b: 2011 - 2012 Alimta Sales Geographic Breakdown ($ bn)
  • Table 5.2.1.c: Alimta Sales & Forecast: 2013-2023
  • Table 5.2.2.a: Xeloda Sales: 2008-2012
  • Table 5.2.2.b: 2011 - 2012 Xeloda Sales Geographic Breakdown ($ m)
  • Table 5.2.2.c: Xeloda Sales & Forecast: 2013-2023
  • Table 5.2.3.a: Eloxatin Sales: 2008-2012
  • Table 5.2.3.b: 2011 - 2012 Eloxatin Sales Geographic Breakdown ($ bn)
  • Table 5.2.3.c: Eloxatin Sales & Forecast: 2013-2023
  • Table 5.2.4.a: Temodar Sales: 2008-2012
  • Table 5.2.4.b: Temodar Sales & Forecast: 2013-2023
  • Table 5.2.5.a: Vidaza Sales: 2008-2012
  • Table 5.2.5.b: Vidaza Sales & Forecast: 2013-2023
  • Table 5.2.6.a: Taxotere Sales: 2008-2012
  • Table 5.2.6.b: 2011 - 2012 Taxotere Sales Geographic Breakdown ($ bn)
  • Table 5.2.6.c: Taxotere Sales & Forecast: 2013-2023
  • Table 5.2.7.a: Treanda Sales: 2008-2012
  • Table 5.2.7.b: Treanda Sales & Forecast: 2013-2023
  • Table 5.3 Market Size & Forecast - Immunotherapy Market 2013-2023
  • Table 5.3.1.a: Revlimid Sales: 2008-2012
  • Table 5.3.1.b: Revlimid Sales & Forecast: 2013-2023
  • Table 5.3.2.a: Gardasil Sales: 2008-2012
  • Table 5.3.2.b: Gardasil Sales & Forecast: 2013-2023
  • Table 5.3.3.a: Zometa Sales: 2008-2012
  • Table 5.3.3.b: 2011 - 2012 Zometa Sales Geographic Breakdown ($/m)
  • Table 5.3.3.c: Zometa Sales & Forecast: 2013-2023
  • Table 5.3.4.a: Global Hormone Therapy Market for Cancer Treatment: 2008-2012
  • Table 5.3.4.b Market Size & Forecast - Hormone Therapy Market 2013-2023
  • Table 5.4.1.a: Faslodex Sales: 2008-2012
  • Table 5.4.1.b: 2011 - 2012 Faslodex Sales Geographic Breakdown ($ m)
  • Table 5.4.1.c: Faslodex Sales & Forecast: 2013-2023
  • Table 5.4.2.a: Zoladex Sales: 2008-2012
  • T able5.4.2.b: 2011 - 2012 Zoladex Sales Geographic Breakdown ($ m)
  • Table 5.4.2.c: Zoladex Sales & Forecast: 2013-2023able
  • Table 5.4.3.a List of generic Anastrozole manufacturing companies in 1 mg tablet type
  • Table 5.4.3.b: Arimidex Sales: 2008-2012
  • Table 5.4.3.c: 2011 - 2012 Arimidex Sales Geographic Breakdown ($ m)
  • Table 5.4.3.d: Arimidex Sales & Forecast: 2013-2023
  • Table 5.4.4.a: Casodex Sales: 2008-2012
  • Table 5.4.4.b: 2011 - 2012 Casodex Sales Geographic Breakdown ($ m)
  • Table 5.4.4.c: Casodex Sales & Forecast: 2013-2023
  • Table 5.4.5.a: Sandostatin Sales: 2008-2012
  • Table 5.4.5.b: 2011 - 2012 Sandostatin Sales Geographic Breakdown ($ m)
  • Table 5.4.5.c: Sandostatin Sales & Forecast: 2013-2023
  • Table 6.1a Oncology Drug - Recent Approvals
  • Table 6.1b Oncology Drug Pipeline - Top 5 Late-stage Cancer Drugs
  • Table 6.1c Oncology Drug Pipeline - Top 10 Experimental Cancer Drugs
  • Table 6.1d Oncology Drug Pipeline - Cancer Drugs Failures
  • Table 7.1 Key Emerging Countries Population Forecasts, 2013, 2018 & 2023
  • Table 7.2 Key Cancer Drugs Patent Expirations
  • Table 7.3 Revenue loss due to Generic Competition
  • Table 7.4 Future Revenue loss due to Generic Competition
  • Table 8.a: The Global Oncology Market Forecast 2013 -2023, by Country ($ bn)
  • Table 8.b Key Countries CAGR 2013-2023 (%)
  • Table 8.c Estimated Global Oncology Market Share for Selected Countries 2013, 2018 and 2023 (%)
  • Table8.d: Total Healthcare Spending and Healthcare Expenditure per Capita 2011, Sample countries ($/p/a)
  • Table 8.1.1: The US Oncology Market Forecast 2013-2023 ($bn)
  • Table 8.1.2 Estimated Rates of Cancer in the US / Survival Rate 2012
  • Table 8.2.1: The UK Oncology Market Forecast 2013-2023 ($bn)
  • Table 8.2.2: The UK's national CDF list
  • Table 8.3.1: The French Oncology Market Forecast 2013-2023 ($ bn)
  • Table 8.4.1: The German Oncology Market Forecast 2013-2023 ($ bn)
  • Table 8.4.2: Germany Cancer Statistics
  • Table 8.5.1: The Spanish Oncology Market Forecast 2013-2023 ($ bn)
  • Table 8.6.1: The Italian Oncology Market Forecast 2013-2023 ($ bn)
  • Table 8.6.2: Percentage of patient access to oncology medicines by Italian region
  • Table 8.6.3: Major cancer drug prices in Italy (INCORRECT CHART BELOW)
  • Table 8.7.1: The Japanese Oncology Market Forecast 2013-2023 ($ bn)
  • Table 8.8.1: The ROW Oncology Market Forecast 2013-2023 ($ bn)
  • Table 8.2.2: BRIC Population, Healthcare Expenditure per Capita
  • Table 8.2.3 Estimated Oncology Market Share for Selected Countries 2013, 2018 and 2023 (%)
  • Table 9.1.1. Amgen Oncology Product overview
  • Table 9.1.2. Amgen Oncology Product pipeline
  • Table 9.2.1 Arida Oncology Product overview
  • Table 9.2.2 Product pipeline
  • Table 9.3.1 Astellas Oncology Products Overview
  • Table 9.3.2 Astellas Oncology Product Pipeline
  • Table 9.4.1 AstraZeneca Oncology Product pipeline
  • Table 9.5.1 Bayer healthcare pharmaceuticals Oncology Product overview
  • Table 9.5.2 Bayer healthcare pharmaceuticals Oncology Product pipeline
  • Table 9.6.1 Boehringer Ingelheim Oncology Product overview
  • Table 9.6.2 Boehringer Ingelheim Oncology Product pipeline
  • Table 9.7.1 Bristol-Myers Squibb Oncology Products Overview
  • Table 9.7.2 Bristol-Myers Squibb Oncology Pipeline Projects
  • Table 9.8.1 Celgene oncology Product overview
  • Table 9.8.2 Celgene oncology Product pipeline
  • Table 9.9.1 Eisai Co., Ltd. Oncology Product overview
  • Table 9.9.2 Eisai Co., Ltd. Oncology Product pipeline
  • Table 9.10.1 Eli Lilly & Co oncology Products Overview
  • Table 9.10.2 Eli Lilly & Co oncology Pipeline Product
  • Table 9.11.1 ImClone Systems Inc. Oncology Product pipeline
  • Table 9.12.1 Exelixis Oncology Products Overview
  • Table 9.12.2 Exelixis Oncology Pipeline Projects
  • Table 9.13.1 GlaxoSmithKline Oncology Product overview
  • Table 9.13.2 GlaxoSmithKline Oncology Product pipeline
  • Table 9.13.3 GlaxoSmithKline Oncology Product Antigen-specific cancer immunotherapeutic (ASCI)
  • Table 9.14.1 Merck Oncology Products Overview
  • Table 9.14.2 Merck Oncology Merck Pipeline
  • Table 9.15.1 Millennium Pharmaceuticals Oncology Product overview
  • Table 9.15.2 Millennium Pharmaceuticals Oncology Product pipeline
  • Table 9.16.1 Novartis Pharmaceuticals Oncology product overview
  • Table 9.16.2 Novartis Pharmaceuticals Oncology Product pipeline
  • Table 9.17.1 Onyx Pharmaceuticals Oncology Product overview
  • Table 9.17.2 Onyx Pharmaceuticals Oncology Product pipeline
  • Table 9.18.1 Pfizer Inc. Oncology Product overview
  • Table 9.18.2 Pfizer Inc. Oncology Product Pipeline
  • Table 9.19.1 Roche Oncology Products overview
  • Table 9.19.2 Roche Oncology Product pipeline
  • Table 9.20.1 Sanofi Oncology Product overview
  • Table 9.20.2 Sanofi Oncology Product pipeline
  • Table 9.21.1 Teva Pharmaceuticals Industries Oncology Product overview
  • Table 9.21.2 Teva Pharmaceuticals Industries Oncology Product pipeline

List of Figures

  • Figure 2.1.1.1 Blood Cancer Type - Incidences
  • Figure 2.1.2.1: Global Breakdown of types of Bone Cancer
  • Figure2.1.11 Global Market Size as per Lung Cancer Type - Incidences
  • Figure 2.1.12 Global Market Size as per Skin Cancer Type - Incidences
  • Figure2.2.1a Global Cancer Market as per Incidences
  • Figure2.2.2a Global Cancer Market by Mortality & Survival
  • Figure 5.1.a: Global Targeted Therapy Market for Cancer Treatment: 2008-2012
  • Figure 5.1.b: 2012 Targeted Therapy Market by Major Drugs
  • Figure 5.1.c: 2012 Other Targeted Therapy Drugs Market Share
  • Figure 5.1d: Global Targeted Therapy Market for Cancer Treatment: 2013-2023
  • Figure 5.1.1.a: 2012 Rituxan Sales Geographic Breakdown
  • Figure 5.1.1.b: Rituxan Sales: 2008-2012
  • Figure 5.1.1.c: Rituxan Sales & Forecast: 2013-2023
  • Figure 5.1.2.1: Herceptin Sales: 2008-2012
  • Figure 5.1.2.2: 2012 Herceptin Sales Geographic Breakdown
  • Figure 5.1.2.3: Herceptin Sales & Forecast: 2013-2023
  • Figure 5.1.3.1: Avastin Sales: 2008-2012
  • Figure 5.1.3.2: 2012 Avastin Sales Geographic Breakdown
  • Figure 5.1.3.3: Avastin Sales & Forecast: 2013-2023
  • Figure 5.1.4.1: Gleevec Sales: 2008-2012
Back to Top